DK1904102T3 - ANTI-CCR7-receptorantistoffer til behandling af cancer - Google Patents

ANTI-CCR7-receptorantistoffer til behandling af cancer

Info

Publication number
DK1904102T3
DK1904102T3 DK06776128.8T DK06776128T DK1904102T3 DK 1904102 T3 DK1904102 T3 DK 1904102T3 DK 06776128 T DK06776128 T DK 06776128T DK 1904102 T3 DK1904102 T3 DK 1904102T3
Authority
DK
Denmark
Prior art keywords
ccr7 receptor
cancer
treatment
receptor antibodies
antibodies
Prior art date
Application number
DK06776128.8T
Other languages
Danish (da)
English (en)
Inventor
Giral Sonia Lopez
Calleja Cecilia Munoz
Perez Manuel Jesus Alfonso
Original Assignee
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Madrid Autonoma filed Critical Univ Madrid Autonoma
Application granted granted Critical
Publication of DK1904102T3 publication Critical patent/DK1904102T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06776128.8T 2005-07-06 2006-07-05 ANTI-CCR7-receptorantistoffer til behandling af cancer DK1904102T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
PCT/EP2006/006556 WO2007003426A1 (en) 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK1904102T3 true DK1904102T3 (da) 2010-04-19

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06776128.8T DK1904102T3 (da) 2005-07-06 2006-07-05 ANTI-CCR7-receptorantistoffer til behandling af cancer

Country Status (16)

Country Link
US (1) US8066996B2 (https=)
EP (1) EP1904102B1 (https=)
JP (1) JP5249025B2 (https=)
KR (1) KR20080030655A (https=)
CN (1) CN101257923A (https=)
AT (1) ATE453407T1 (https=)
AU (1) AU2006265281C1 (https=)
BR (1) BRPI0612632A2 (https=)
CA (1) CA2614080C (https=)
DE (1) DE602006011466D1 (https=)
DK (1) DK1904102T3 (https=)
ES (1) ES2338919T3 (https=)
IL (1) IL188594A (https=)
PT (1) PT1904102E (https=)
RU (1) RU2404808C2 (https=)
WO (2) WO2007003216A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
EP2285403A2 (en) * 2008-05-14 2011-02-23 Msm Protein Technologies, Inc. Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
JP5801202B2 (ja) * 2009-09-29 2015-10-28 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
EP2623592B1 (en) 2010-09-28 2019-05-15 NB Health Laboratory Co. Ltd. Anti-human ccr7 antibodies, hybridoma, medicinal composition, and antibody-immobilized carrier
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EP2970483A2 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2015147335A1 (ja) * 2014-03-27 2015-10-01 国立大学法人大阪大学 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
DK3334457T3 (da) * 2015-08-10 2020-09-21 Pepmab B V Humaniserede anti-CCR7-receptorantistoffer
EP3858993A1 (en) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN113557244A (zh) * 2018-12-18 2021-10-26 弹射器治疗有限公司 预防或治疗移植物抗宿主病(GvHD)的抗CCR7 mAb的用途
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005002628A1 (en) * 2003-06-11 2005-01-13 The University Of Chicago Increased t-cell tumor infiltration by mutant light

Also Published As

Publication number Publication date
RU2008104420A (ru) 2009-08-20
ATE453407T1 (de) 2010-01-15
JP5249025B2 (ja) 2013-07-31
WO2007003426A1 (en) 2007-01-11
AU2006265281A1 (en) 2007-01-11
CN101257923A (zh) 2008-09-03
CA2614080A1 (en) 2007-01-11
JP2008545000A (ja) 2008-12-11
AU2006265281C1 (en) 2012-11-15
KR20080030655A (ko) 2008-04-04
ES2338919T3 (es) 2010-05-13
RU2404808C2 (ru) 2010-11-27
EP1904102A1 (en) 2008-04-02
EP1904102B1 (en) 2009-12-30
BRPI0612632A2 (pt) 2012-01-03
DE602006011466D1 (de) 2010-02-11
US8066996B2 (en) 2011-11-29
IL188594A0 (en) 2008-04-13
PT1904102E (pt) 2010-03-29
US20090123483A1 (en) 2009-05-14
WO2007003216A1 (en) 2007-01-11
AU2006265281B2 (en) 2012-03-01
CA2614080C (en) 2014-08-26
IL188594A (en) 2012-02-29

Similar Documents

Publication Publication Date Title
IL188594A0 (en) Anti-ccr7 receptor antibodies for the treatment of cancer
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
CR20120105A (es) Proteínas terapéuticas de unión a dll4
EA201170716A1 (ru) Антитела к с-мет
EA200971077A1 (ru) Гетероциклические модуляторы киназы
MX373790B (es) Anticuerpos humanos a ligando de muerte programada 1 (pd-l1).
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
CY1122132T1 (el) Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης
EA201100923A1 (ru) Антитела человека против тканевого фактора
GEAP202014811A (en) Ctla4 binders
BR112016025437A2 (pt) combinação de lenalidomida e construto de polipeptídeo, e usos destes
MX2021003436A (es) Anticuerpos humanos para pd-1.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA201591762A1 (ru) Человеческие антитела к grem1
ATE528319T1 (de) Krebsbehandlung mit anti-il-1-antikörpern
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
DK3806895T5 (da) Antistoffer der binder tumorvæv, og deres diagnostiske og terapeutiske anvendelser
AR093671A1 (es) Anticuerpos monoclonales contra una proteina activada c (apc)
MY204733A (en) Anti-pd-l1 antibodies and use thereof